AIM: To investigate protease activated receptor 2 (PAR-2) expression in human coronary atherosclerotic lesions because PAR-2 is involved in the modulation of inflammatory events and vascular function. METHODS: An immunohistochemical analysis was performed on serial arterial sections, using the following antibodies: MDA2, a murine monoclonal antibody against malondialdehyde lysine epitopes of oxidised low density lipoprotein (oxLDL); HAM-56, a monoclonal antibody against human macrophages/foam cells; B5, a rabbit polyclonal antibody against PAR-2; and SAM11, a mouse monoclonal antibody against human PAR-2. Sections containing at least one lesion showing substantial immunostaining were counted as positive, and results were expressed as per cent of all sections of the same artery. RESULTS: PAR-2 expression was enhanced in human coronary atherosclerotic lesions. This phenomenon correlated with an increase in oxLDL epitopes in the coronary artery. CONCLUSION: This study shows for the first time that PAR-2 expression is enhanced in human coronary atherosclerotic lesions, and suggests that PAR-2 dependent cellular trafficking may be one of the regulatory signalling responses to vascular injury. Further pharmacological studies will establish whether modulation (and in which direction) of PAR-2 represents a possible therapeutic target for controlling the vascular response to injury.
AIM: To investigate protease activated receptor 2 (PAR-2) expression in humancoronary atherosclerotic lesions because PAR-2 is involved in the modulation of inflammatory events and vascular function. METHODS: An immunohistochemical analysis was performed on serial arterial sections, using the following antibodies: MDA2, a murine monoclonal antibody against malondialdehydelysine epitopes of oxidised low density lipoprotein (oxLDL); HAM-56, a monoclonal antibody against human macrophages/foam cells; B5, a rabbit polyclonal antibody against PAR-2; and SAM11, a mouse monoclonal antibody against humanPAR-2. Sections containing at least one lesion showing substantial immunostaining were counted as positive, and results were expressed as per cent of all sections of the same artery. RESULTS:PAR-2 expression was enhanced in humancoronary atherosclerotic lesions. This phenomenon correlated with an increase in oxLDL epitopes in the coronary artery. CONCLUSION: This study shows for the first time that PAR-2 expression is enhanced in humancoronary atherosclerotic lesions, and suggests that PAR-2 dependent cellular trafficking may be one of the regulatory signalling responses to vascular injury. Further pharmacological studies will establish whether modulation (and in which direction) of PAR-2 represents a possible therapeutic target for controlling the vascular response to injury.
Authors: Claudio Napoli; Filomena De Nigris; Carla Cicala; John L Wallace; Giuseppe Caliendo; Mario Condorelli; Vincenzo Santagada; Giuseppe Cirino Journal: Am J Physiol Heart Circ Physiol Date: 2002-06 Impact factor: 4.733
Authors: F P D'Armiento; A Bianchi; F de Nigris; D M Capuzzi; M R D'Armiento; G Crimi; P Abete; W Palinski; M Condorelli; C Napoli Journal: Stroke Date: 2001-11 Impact factor: 7.914
Authors: Anna F Milia; Maria B Salis; Tiziana Stacca; Alessandra Pinna; Paolo Madeddu; Marcello Trevisani; Pierangelo Geppetti; Costanza Emanueli Journal: Circ Res Date: 2002-08-23 Impact factor: 17.367
Authors: Shannon M Jones; Adrien Mann; Kelsey Conrad; Keith Saum; David E Hall; Lisa M McKinney; Nathan Robbins; Joel Thompson; Abigail D Peairs; Eric Camerer; Katey J Rayner; Michael Tranter; Nigel Mackman; A Phillip Owens Journal: Arterioscler Thromb Vasc Biol Date: 2018-03-29 Impact factor: 8.311
Authors: Hao Chen; Donghang Zheng; Sriram Ambadapadi; Jennifer Davids; Sally Ryden; Hazem Samy; Mee Bartee; Eric Sobel; Erbin Dai; Liying Liu; Colin Macaulay; Anthony Yachnis; Cornelia Weyand; Robert Thoburn; Alexandra Lucas Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240